The FDA approved the use of pembrolizumab in combination with chemotherapy for adults with primary advanced or recurrent endometrial carcinoma.
Pembrolizumab (Keytruda, Merck) — an anti-PD-1 therapy — has been approved for several indications to treat gynecologic cancers, including two for advanced endometrial carcinoma. The application for this newest indication received priority review by the FDA.
The agency based its approval on results from the randomized KEYNOTE-868/NRG-GY018 trial assessing efficacy and safety of the regimen in 810 women with advanced or recurrent endometrial